Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 16/20 | 0.51 |
| ▸ | HTR6 | P50406 | 16/20 | 0.51 |
| ▸ | HTR2A | P28223 | 14/20 | 0.51 |
| ▸ | DRD2 | P14416 | 13/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064463 | 0.98 | HTR7 (0.52) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL792396 | 0.86 | HTR7 (0.54) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL791038 | 0.86 | DRD2 (0.51) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL15064247 | 0.85 | HTR7 (0.57) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL15064828 | 0.84 | HTR7 (0.56) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL793126 | 0.83 | DRD2 (0.53) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL15064224 | 0.83 | HTR6 (0.51) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL791804 | 0.83 | HTR7 (0.55) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL791206 | 0.83 | DRD2 (0.53) | HTR7HTR6HTR2ADRD2DRD3 | |
| SCHEMBL792247 | 0.83 | HTR1A (0.54) | HTR7HTR6HTR2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | HTR7 1419/4885HTR6 1131/4885HTR2A 1150/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | HTR7 1419/4885HTR6 1131/4885HTR2A 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.